Literature DB >> 22253366

Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health.

Rodney A Hayward1, Harlan M Krumholz.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22253366     DOI： 10.1161/CIRCOUTCOMES.111.964676

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN： 1941-7713


× No keyword cloud information.
  35 in total

1.  Niacin added to statins for cardiovascular disease.

Authors:  Michael R Kolber; Noah Ivers; G Michael Allan
Journal:  Can Fam Physician       Date:  2012-08       Impact factor: 3.275

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  The problem with cardiovascular disease prevention guidelines.

Authors:  Jay N Cohn; Daniel A Duprez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

Review 4.  CVD screening in low-risk, asymptomatic adults: clinical trials needed.

Authors:  Tamar S Polonsky; Philip Greenland
Journal:  Nat Rev Cardiol       Date:  2012-08-14       Impact factor: 32.419

Review 5.  Evolution of lipid management guidelines: evidence might set you free.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

Review 6.  Problems and possible solutions for therapy with statins.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2013-06

Review 7.  Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2016-12-12

Review 8.  Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk.

Authors:  Morton Leibowitz; Chandra Cohen-Stavi; Sanjay Basu; Ran D Balicer
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

Review 9.  Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2013-11       Impact factor: 3.275

10.  Using benefit-based tailored treatment to improve the use of antihypertensive medications.

Authors:  Jeremy Sussman; Sandeep Vijan; Rod Hayward
Journal:  Circulation       Date:  2013-11-04       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.